Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.
Serum samples from 36 cervical carcinoma patients, 33 patients with high-grade squamous intraepithelial lesions, and 31 cytologically normal women were tested by enzyme-linked immunosorbent assay (ELISA) using human papilloma virus type 6 (HPV 6) and HPV 16 virus-like particles as antigens. Forty serum specimens from 1-year-old children were used to assign cutoff points. When serum samples from the subjects infected with HPV 16 were tested in an HPV 16 ELISA detecting immunoglobulin A (IgA), IgG, and IgM binding, 61% showed IgA, 44% showed IgG, and 39% showed IgM reactivity. Of HPV 6- or 11- or HPV 18-infected subjects. fewer than 17% showed IgA or IgG responses and 33% showed IgM reactivity. In contrast, 13% showed IgA, 10% showed IgG, and 16% showed IgM reactivity in the HPV DNA-negative controls. The results suggest that the IgA and IgG responses are HPV 16 specific and the IgM response is cross-reactive to different HPV types. On the other hand, the serological responses to HPV 6 did not differ in the patient and control groups. The percentages of patients positive for both IgA and IgG antibodies were significantly higher in the groups with high-grade squamous intraepithelial lesions (12% [4 of 33]; P = 0.04) and cancer (17% [6 of 36]; P = 0.02) than in the healty women (0% [0 of 31]), and the percentages for either IgA or IgG were higher for the cancer group (47% [17 of 36]; P = 0.01) than in the normal group (19% [6 of 31]). Most sera positive for IgA and IgG in the patient groups showed higher titers than those in the normal group. All these results suggest that high IgA and IgG responses are good indicators for estimating HPV 16 infection.
Sasagawa
T
T
Imperial Cancer Research Fund Tumour Virus Group, University of Cambridge, London, United Kingdom.
Inoue
M
M
Lehtinen
M
M
Zhang
W
W
Gschmeissner
S E
SE
Hajibagheri
M A
MA
Finch
J
J
Crawford
L
L
D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology*; D002213:Capsid / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000821:virology; D003218:Condylomata Acuminata / Q000276:immunology / Q000821:virology; D003429:Cross Reactions / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007075:Immunoglobulin M / Q000097:blood / Q000276:immunology; D007223:Infant; D016253:Microscopy, Immunoelectron; D008875:Middle Aged; D027383:Papillomaviridae / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000821:virology*; D002578:Uterine Cervical Dysplasia / Q000276:immunology* / Q000821:virology
D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M